$SNDA

SNDA Upgraded by Baird -- Price Target Raised to $43.00

Sonida Senior Living (SNDA) was upgraded to Outperform by Baird, with a price target raised to $43.00. The stock is considered overvalued by 109.1% according to GuruFocus, with a GF Score of 50/100. Insiders have sold $10.9M in shares recently, while analysts see growth potential.

Original reporting
Published Sep 4, 2026, 2:25 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 3:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$SNDA
Bullish
medium confidence
Mentioned
$SNDA
Relevance
7/10
alphai data visualization · based on gurufocus.com
Decision brief

The 30-second read

$SNDABullishMed
01

Why it matters

The Baird upgrade signals a more favorable outlook, but valuation concerns remain.

02

Market read

Analyst upgrade may prompt short‑term buying interest, though valuation risks limit broader market impact.

03

What to watch

High insider selling and weak valuation metrics could dampen the upside from the upgrade.

Relevance 7/10Novelty 6/10Timing: no immediate timing

Background

Sonida Senior Living (SNDA) operates senior‑living facilities in the U.S. and has a market cap of ~ $1.86 B.

Company-level read

Ticker impact

$SNDABullishMedium confidence
Context

Baird upgraded Sonida Senior Living to Outperform and raised the price target to $43.

Expected impact

Potential upside of 5‑10% if market reacts to the higher target.

Evidence & confidence

Upgrade is a fresh analyst opinion with a concrete target, but the stock is already overvalued per GF metrics.

Market effects

May lift sentiment in the senior‑living healthcare sector as peers could see similar upgrades.

Limited to U.S. healthcare providers; no broader regional effect.

Low global relevance; impact confined to U.S. listed senior‑living stocks.

Counterpoint

The stock appears significantly overvalued (109% above GF value) despite the upgrade, suggesting caution.

Key entities

  • Sonida Senior Living Inc

    U.S. senior‑living provider receiving the upgrade.

  • Baird

    Research firm that upgraded SNDA to Outperform.

Related articles

$SNDAMedAI 8/10

SONIDA SENIOR LIVING, INC. (SNDA): Results of Operations and Financial Condition

SONIDA SENIOR LIVING, INC. (SNDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sonida Senior Living Announces Second Quarter 2026 Results DALLAS, Texas – August 10, 2026 – Sonida Senior Living, Inc. (the “Company,” “Sonida,” “we,” “our,” or “us”) (NYSE: SNDA), a leading owner, operator and investor of senior housing communities, today announced

$DYNMed

Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX,

Biotech and healthcare stocks hit 52-week highs on July 27, 2026. Dyne Therapeutics (DYN) rose over 5% to $26.12 after FDA accepted its Z-Rostudirsen BLA; it raised $431m. Sonida Senior Living (SNDA) reached $44.38 after its CHP acquisition. Silence Therapeutics (SLN) hit $12.19. Amylyx (AMLX) rose to $19.60. Labcorp (LH) climbed to $301.7 after launching a genetic testing platform; Q1 revenue was $3.54b and 2026 revenue guidance $14.65b-$14.80b.

$SNDAMed

Sunda Energy (LON:SNDA) Sets New 52

Sunda Energy Plc (LON:SNDA) shares hit a new 52-week low on Thursday, trading as low as 1.60p and last at 1.70p versus a prior close of 1.82p, with 2.21m shares traded. The stock was down 11.1%. The company’s market cap is £5.52m, with a negative P/E of -2.00.

$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

$MOMOMed

StoneX cuts Hello Group stock price target on weaker outlook

StoneX reduced its price target for Hello Group (MOMO) to $8.00 from $10.00, citing weaker domestic spending and moderating overseas growth. The company's Q2 2026 revenue declined 5% YoY, though overseas revenue grew 52% YoY. StoneX lowered its fiscal 2026 revenue forecast to a 6% YoY decline. Hello Group's stock trades at $5.39, near its 52-week low, with a P/E ratio of 8.34 and a 5.1% dividend yield.